In Vitro |
Linderalactone (0-100 μM; 24 hours; A549 cells) treatment inhibits the growth of A549 cells concentration-dependently. The IC50 of linderalactone is 15 µM[1]. Linderalactone (7.5-30 μM; A549 cells) treatment induces apoptosis in A549 cells in a dose-dependent manner[1]. Linderalactone (7.5-30 μM; 24 hours; A549 cells) treatment induces G2/M cell cycle arrest of A549 cells dose-dependently[1]. Linderalactone (7.5-30 μM; A549 cells) inhibits the expression of STAT1, JAK1 and JAK2. Linderalactone could also inhibit the phosphorylation of pSTAT1, pSTAT-2, pJAK1 and pJAk2[1]. Cell Viability Assay[1] Cell Line: Lung cancer A549 cells Concentration: 0 μM, 1.6 μM, 3.2 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM Incubation Time: 24 hours Result: Inhibited the growth of A549 cells concentration-dependently. Apoptosis Analysis[1] Cell Line: Lung cancer A549 cells Concentration: 7.5 μM, 15 μM, 30 μM Incubation Time: Result: Induced apoptosis in A549 cells in a dose-dependent manner. Cell Cycle Analysis[1] Cell Line: Lung cancer A549 cells Concentration: 7.5 μM, 15 μM, 30 μM Incubation Time: 24 hours Result: Induced G2/M cell cycle arrest. Western Blot Analysis[1] Cell Line: Lung cancer A549 cells Concentration: 7.5 μM, 15 μM, 30 μM Incubation Time: Result: Inhibited the JAK/STAT pathway in A549 cells.
|